Argocytes Containing Enzyme Nanoparticles Reduce Toxic Concentrations of Arginine in the Blood

• Published in: Bulletin of experimental biology and medicine Vol. 153; no. 3; pp. 406 - 408
• Main Authors: Kaminsky, Yu. G., Kosenko, E. A.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-07-2012; Springer; Springer Nature B.V
• Subjects: Animals; Arginase; Arginase - administration & dosage; Arginase - chemistry; Arginase - therapeutic use; Arginine; Arginine - blood; Biomedical and Life Sciences; Biomedicine; Blood; Blood levels; Cell Biology; Cells, Cultured; Enzymes; Erythrocytes; Erythrocytes - chemistry; Erythrocytes - metabolism; Hyperargininemia - drug therapy; Internal Medicine; Laboratory Medicine; Mice; Nanoparticles; Nanoparticles - chemistry; Nanotechnology; ornithine; Pathology; Urea; argocytes; plasma arginine; nanobiotechnology; erythrocytes; arginase encapsulation
• DOI: 10.1007/s10517-012-1727-3
• EISSN: 1573-8221
• ISSN: 0007-4888

A method for incorporation of arginase nanoparticles into mouse erythrocytes has been developed and the possibility of reducing blood arginine concentration in animals with experimental hyperargininemia with arginase-loaded erythrocytes (argocytes) has been studied. Argocyte infusion to animals with hyperargininemia led to a rapid decrease in blood arginine concentration within 1 h and this effect of argocytes persisted for at least 4 h. This was paralleled by an increase in plasma concentrations of urea and ornithine. Hence, plasma arginine is hydrolyzed by arginase incorporated into argocytes; argocytes are functionally active and can serve as a defense system in pathological hyperargininemia, while the method developed by us can be regarded as a new nanobiotechnology for medicine and veterinary.